Type-2 diabetes is increasing in prevalence at an alarming rate. The underlying cause of this disease is still not known. Patients with TTDM have insulin resistance and defective insulin secretion. It has been known for almost 30 years that insulin is secreted in high frequency intermittent pulses. However as these pulses result in only small oscillations in insulin concentration in the usual blood sampling sites, they have been hard to study. The laboratory of the PI in collaboration with Johannes Veldhuis at the University of Virginia have developed and validated methods that can now reliably quantify pulsatile insulin secretion in humans. Studies with these methods have revealed that almost all insulin is secreted in these intermittent pulses which occur at 6-minute intervals. We have also shown that the regulation of insulin secretion (for example after a meal) is achieved by the amplification of these pulses. Also, the liver is normally exposed to huge insulin concentration changes as these pulses are secreted into the portal vein that drains to the liver. No prior studies have examined the importance of these masses pulses on insulin action. In the present studies we plan to first establish how insulin secretion after meal ingestion is disturbed in patients with TTDM. We suspect that it will be deficient because the size of the insulin pulses is greatly decreased. Further, we suspect that this is because the number of cells that secrete insulin are decreased. We will test this by removing approximately 40 percent and 70 percent of these cells in a dog model with the expectation that we will create the same defect present in TTDM. We will also establish how important it is that the liver be exposed to these large insulin concentrations to function normally. This is important since patients with diabetes have to treat themselves with insulin in a very different manner. Designers of future systems to replace insulin in patients (e.g. by transplantation or devices) need to be appraised of the importance of pulsatile insulin secretion insulin action.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK061539-04
Application #
6940796
Study Section
Metabolism Study Section (MET)
Program Officer
Appel, Michael C
Project Start
2002-07-01
Project End
2007-05-31
Budget Start
2005-06-01
Budget End
2007-05-31
Support Year
4
Fiscal Year
2005
Total Cost
$433,839
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Butler, Peter C; Elashoff, Michael; Elashoff, Robert et al. (2013) A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care 36:2118-25
Costes, Safia; Langen, Ralf; Gurlo, Tatyana et al. (2013) ?-Cell failure in type 2 diabetes: a case of asking too much of too few? Diabetes 62:327-35
Butler, Alexandra E; Campbell-Thompson, Martha; Gurlo, Tatyana et al. (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62:2595-604
Butler, A E; Robertson, R P; Hernandez, R et al. (2012) Beta cell nuclear musculoaponeurotic fibrosarcoma oncogene family A (MafA) is deficient in type 2 diabetes. Diabetologia 55:2985-8
Pedersen, Morten Gram; Dalla Man, Chiara; Cobelli, Claudio (2011) Multiscale modeling of insulin secretion. IEEE Trans Biomed Eng 58:3020-3
Bostrom, Kristina I; Jumabay, Medet; Matveyenko, Aleksey et al. (2011) Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res 108:446-57
Butler, A E; Cao-Minh, L; Galasso, R et al. (2010) Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 53:2167-76
Ritzel, Robert A; Jayasinghe, Sajith; Hansen, John B et al. (2010) Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regul Pept 165:158-62
Bedrood, Sahar; Jayasinghe, Sajith; Sieburth, Derek et al. (2009) Annexin A5 directly interacts with amyloidogenic proteins and reduces their toxicity. Biochemistry 48:10568-76
Matveyenko, A V; Butler, P C (2008) Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab 10 Suppl 4:23-31

Showing the most recent 10 out of 26 publications